This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.
Ecolab Brings Direct-to-Chip Cooling Monitoring to Southeast Asia
by Zacks Equity Research
ECL debuts its 3D TRASAR direct-to-chip cooling monitoring in Singapore, boosting efficiency and sustainability in data centers.
OMI Reshapes Portfolio With $375 Million Sale to Platinum Equity
by Zacks Equity Research
Owens & Minor sharpens its focus on home-based care with a $375M divestiture to Platinum Equity, unlocking cash, tax benefits, and long-term upside through a retained equity stake.
ISRG Shares Rise as FDA Clears AI Integration for Ion Platform
by Zacks Equity Research
Intuitive Surgical shares climb after FDA clears AI-driven upgrades for its Ion platform, boosting precision and efficiency in lung biopsies.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL's robust product lineup, innovation-driven growth and strong Q2 results underscore its long-term potential despite macroeconomic headwinds.
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
by Zacks Equity Research
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
CAH Expands Distribution Network With Indianapolis Facility
by Zacks Equity Research
Cardinal Health accelerates its multi-year supply chain transformation with a new flagship Indianapolis distribution center, reinforcing automation-driven efficiency while building on recent logistics expansions in Ohio and Texas.
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment
by Zacks Equity Research
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
HTFL Gains FDA Clearance & Cigna Coverage for Next Gen Plaque Analysis
by Zacks Equity Research
Heartflow secures FDA clearance and Cigna coverage for its Next Gen Plaque Analysis, boosting accuracy and nationwide access.
TMDX Partners With Mercedes-Benz to Launch Organ Transport Network
by Zacks Equity Research
TransMedics collaborates with Mercedes-Benz to launch Italy's first organ transport network, expanding its OCS model beyond the United States.